Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the antibody-drug conjugate (ADC) last year, but investors sent Corbus’ stock down 10% in premarket trading.
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the antibody-drug conjugate (ADC) last year, but investors sent Corbus’ stock down 10% in premarket trading.
